Cargando…
Role of HMGB1 in Cutaneous Melanoma: State of the Art
High-mobility Group Box 1 (HMGB1) is a nuclear protein that plays a key role in acute and chronic inflammation. It has already been studied in several diseases, among them melanoma. Indeed, HMGB1 is closely associated with cell survival and proliferation and may be directly involved in tumor cell me...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409290/ https://www.ncbi.nlm.nih.gov/pubmed/36012593 http://dx.doi.org/10.3390/ijms23169327 |
_version_ | 1784774815450660864 |
---|---|
author | Li Pomi, Federica Borgia, Francesco Custurone, Paolo Vaccaro, Mario Pioggia, Giovanni Gangemi, Sebastiano |
author_facet | Li Pomi, Federica Borgia, Francesco Custurone, Paolo Vaccaro, Mario Pioggia, Giovanni Gangemi, Sebastiano |
author_sort | Li Pomi, Federica |
collection | PubMed |
description | High-mobility Group Box 1 (HMGB1) is a nuclear protein that plays a key role in acute and chronic inflammation. It has already been studied in several diseases, among them melanoma. Indeed, HMGB1 is closely associated with cell survival and proliferation and may be directly involved in tumor cell metastasis development thanks to its ability to promote cell migration. This research aims to assess the role of this molecule in the pathogenesis of human melanoma and its potential therapeutic role. The research has been conducted on the PubMed database, and the resulting articles are sorted by year of publication, showing an increasing interest in the last five years. The results showed that HMGB1 plays a crucial role in the pathogenesis of skin cancer, prognosis, and therapeutical response to therapy. Traditional therapies target this molecule indirectly, but future perspectives could include the development of new target therapy against HMGB1, thus adding a new approach to the therapy, which has often shown primary and secondary resistance. This could add a new therapy arm which has to be prolonged and specific for each patient. |
format | Online Article Text |
id | pubmed-9409290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94092902022-08-26 Role of HMGB1 in Cutaneous Melanoma: State of the Art Li Pomi, Federica Borgia, Francesco Custurone, Paolo Vaccaro, Mario Pioggia, Giovanni Gangemi, Sebastiano Int J Mol Sci Review High-mobility Group Box 1 (HMGB1) is a nuclear protein that plays a key role in acute and chronic inflammation. It has already been studied in several diseases, among them melanoma. Indeed, HMGB1 is closely associated with cell survival and proliferation and may be directly involved in tumor cell metastasis development thanks to its ability to promote cell migration. This research aims to assess the role of this molecule in the pathogenesis of human melanoma and its potential therapeutic role. The research has been conducted on the PubMed database, and the resulting articles are sorted by year of publication, showing an increasing interest in the last five years. The results showed that HMGB1 plays a crucial role in the pathogenesis of skin cancer, prognosis, and therapeutical response to therapy. Traditional therapies target this molecule indirectly, but future perspectives could include the development of new target therapy against HMGB1, thus adding a new approach to the therapy, which has often shown primary and secondary resistance. This could add a new therapy arm which has to be prolonged and specific for each patient. MDPI 2022-08-18 /pmc/articles/PMC9409290/ /pubmed/36012593 http://dx.doi.org/10.3390/ijms23169327 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Li Pomi, Federica Borgia, Francesco Custurone, Paolo Vaccaro, Mario Pioggia, Giovanni Gangemi, Sebastiano Role of HMGB1 in Cutaneous Melanoma: State of the Art |
title | Role of HMGB1 in Cutaneous Melanoma: State of the Art |
title_full | Role of HMGB1 in Cutaneous Melanoma: State of the Art |
title_fullStr | Role of HMGB1 in Cutaneous Melanoma: State of the Art |
title_full_unstemmed | Role of HMGB1 in Cutaneous Melanoma: State of the Art |
title_short | Role of HMGB1 in Cutaneous Melanoma: State of the Art |
title_sort | role of hmgb1 in cutaneous melanoma: state of the art |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409290/ https://www.ncbi.nlm.nih.gov/pubmed/36012593 http://dx.doi.org/10.3390/ijms23169327 |
work_keys_str_mv | AT lipomifederica roleofhmgb1incutaneousmelanomastateoftheart AT borgiafrancesco roleofhmgb1incutaneousmelanomastateoftheart AT custuronepaolo roleofhmgb1incutaneousmelanomastateoftheart AT vaccaromario roleofhmgb1incutaneousmelanomastateoftheart AT pioggiagiovanni roleofhmgb1incutaneousmelanomastateoftheart AT gangemisebastiano roleofhmgb1incutaneousmelanomastateoftheart |